GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BMS-224818 | LEA29Y | Nulojix®
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class:
Peptide
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids. View more information in the IUPHAR Pharmacology Education Project: belatacept |
Classification ![]() |
|
| Compound class | Peptide |
| Ligand families/groups | Immune checkpoint modulators |
| Approved drug? | Yes. EU EMA (2011) | US FDA (2011) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 8627 | belatacept |
Synonyms ![]() |
| BMS-224818 | LEA29Y | Nulojix® |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 247 |
| Other databases | |
| ChEMBL Ligand | CHEMBL1742990 (Hs) |
| DrugBank Ligand | DB06681 |
| GtoPdb PubChem SID | 178103474 |
| PubChem SID | 135283321 |
| Search PubMed clinical trials | belatacept |
| Search PubMed titles | belatacept |
| Search PubMed titles/abstracts | belatacept |
| Wikipedia | Belatacept |